Foamix Pharmaceuticals

February 21, 2020

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.

Evaluate

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

US FDA approval tracker: October 2019

Go or no go? Novartis eyes a big new growth driver

Perseverance pays off for Foamix

Dermira in a spot of bother after acne failure

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Strong small cap performance drives second-quarter gains

Mid-cap biopharma stocks pick up in the first quarter

Interview – Foamix spots dermatology opportunity

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

Latest Reports

Pharma’s Biggest Spenders 2022 Infographic

Gene Editing: Overhyped or Unstoppable Tide?

Editor's Picks

Heightened US antitrust fears rattle biopharma

2023’s biggest launches: the story so far

Viking’s Voyage is not over yet

Gene editing: overhyped or unstoppable tide?

A slow (and low) year for FDA approvals